Skip to content
15% off your first order15% off your first order

Semaglutide 15 mg vial

Appetite & satiety

Investigated for GLP-1 receptor and satiety signaling.

$69.00CAD· $4.60/mg
1
  • Ships from Canada in 1–2 business days
  • Free shipping over $120
  • Place your order, then send the e-Transfer. We pack it as soon as it arrives.

For research use only. Not for human consumption.

Complete your setup

Needles and wipes are free. Water is $19.

Compare. Side by side, from the research.

About Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist. Research examines its role in glucose-dependent insulin signaling, gastric emptying, and the central pathways registering satiety.

How it works

Incretin Pathway
Studied at the GLP-1 receptor for glucose-dependent insulin release rather than unconditional stimulation.
Gastric Emptying
Explored for slowing the rate at which the stomach empties, associated with prolonged fullness.
Read the full research

What you need

  • Bacteriostatic Water
  • Needles
  • Alcohol Wipes
  • A protocol guide comes with every order

Shipping & payment

  • Packed and dispatched within 1–2 business days
  • Delivered across Canada in 2–5 business days, tracked
  • Temperature-controlled packaging where the product needs it
  • Free shipping on orders over $120
  • Prices in CAD · pay by Interac e-Transfer
Format
Lyophilised powder in a sealed vial
Strength
15 mg per vial
Storage
Refrigerate, away from light. Once reconstituted, keep refrigerated and use within the window on the insert.
Reconstitution
2 mL bacteriostatic water for this 15 mg vial (7.5 mg/mL)
Route in research
Subcutaneous
Target
GLP-1R
SKU
SM15

Handling

  1. 1ReconstituteAdd bacteriostatic water down the side of the vial. Swirl, never shake. Agitation damages the peptide chain.
  2. 2StoreRefrigerate at 2–8°C once mixed. Reconstituted peptide is stable for the window given in your protocol guide.
  3. 3Measure with the calculator Use an insulin syringe at the units your protocol specifies. Rotate sites and log what you take.
Purity
High-performance liquid chromatography (HPLC), by an independent laboratory
Identity
Mass spectrometry, on the same batch
How often
Every batch
COA
The certificate of analysis is matched to the lot code printed on your vial
Evidence
Approved analog

Check your lot

Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.

Approved analogSemaglutide has been evaluated in randomized controlled trials and meta-analyses, and a semaglutide product, Wegovy, has been described in the literature as a weight loss drug for chronic weight management.

What research examines

  • Weight loss in obesity without diabetes
  • Glucose-dependent insulin signaling via the GLP-1 receptor
  • Gastric emptying and satiety signaling
  • Distributed neural pathways of body weight regulation in rodents
  • Heart failure with preserved ejection fraction in observational research
  • Clinical pharmacokinetics and extended half-life

Reported in studies

  • Risk of nonarteritic anterior ischemic optic neuropathy has been examined in patients prescribed semaglutide
  • Effects on lean mass have been reviewed across clinical trials
  • Slowed gastric emptying is a studied mechanism of action
  • Overall safety has been the subject of a dedicated published review
Read the full research page· 5 cited studies

Published research protocols

500 mcg, 1/week, am fasted

Research protocols have used 250–2,000 mcg per administration, once weekly (morning, fasted), stepping up from 250 mcg to 2 mg by week 13. Reported cycle: continuous until target weight loss.

For research use only. These figures summarize published research protocols. They are not instructions or medical advice.

Measure with the calculator

CoreX AI

Ask about Semaglutide

Plain answers, from the basics to the studies.

Research information, not medical advice.

FAQ

Questions, answered

  • Semaglutide is a long-acting GLP-1 receptor agonist. It is described in research as an incretin mimetic carrying structural modifications that extend its half-life. Research examines its role in glucose-dependent insulin signaling, gastric emptying, and the central pathways that register satiety. Published reviews trace its discovery and development alongside liraglutide, an earlier compound in the same class, and a semaglutide product has been described as a weight loss drug for chronic weight management.

  • Semaglutide acts at the GLP-1 receptor. Research describes its effect on insulin release as glucose-dependent rather than unconditional stimulation. It has also been explored for slowing the rate at which the stomach empties, which is associated with prolonged fullness. Rodent work reports that semaglutide lowers body weight through distributed neural pathways, supporting the view that it acts on both peripheral glucose handling and central appetite signaling.

  • Research has studied semaglutide for weight loss in people with obesity without diabetes, including a systematic review and meta-analysis and long-term analyses from the SELECT randomized controlled trial. Other work has examined its clinical pharmacokinetics, its effect on lean mass, the neural pathways involved in body weight reduction in rodents, and outcomes in heart failure with preserved ejection fraction in an observational comparison with tirzepatide.

  • Safety of semaglutide has been summarized in a dedicated published review. A study in JAMA Ophthalmology examined the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide, and a systematic review assessed its effect on lean mass during clinical trials. Slowed gastric emptying is part of its studied mechanism. Detailed adverse event rates are not summarized here, and the primary literature should be consulted for specifics.

  • Research protocols have used 250 to 2,000 mcg per administration, given once weekly in the morning in a fasted state, stepping up from 250 mcg to 2 mg by week 13. The reported cycle is continuous until target weight loss, with a subcutaneous route described. This information reflects research protocols only and is not a recommendation. Each CoreX order ships with a protocol guide for laboratory reference.

Vial · Pen

Dual-agonist weight research

Tirzepatide · 2 sizes

$139/ 30 mg vial

Vial · Pen

Triple-agonist weight research

GLP-3R · 4 sizes

$119/ 10 mg vial